Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

By W. Xia, R. Mullin, B. Keith, Lei-hua Liu, Hong Ma, D. Rusnak, G. Owens, K. Alligood, N. Spector. Oncogene, 2002

679 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/06c99004327da39e6bfe62da75afe52e34024c17

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. P. Dennis

Citations in the corpus

• Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. (2006, background): “cancer cell lines (SKBR3 and UACC-893), which constitutively express an activated HER-2 tyrosine kinase, heregulin h1 does not further increase HER-2 phosphorylation, indicating that this receptor is being maximally activated in these cell lines at baseline (35).”
• Activation of the PI3K/Akt pathway and chemotherapeutic resistance. (2002, methodology): “verified the effects of trastuzumab in vivo using human xenograft or athymic mouse models, respectively (Anderson et al., 2001; Xia et al., 2002).”